MRPS23 is a novel prognostic biomarker and promotes glioma progression
Aging · 31.01.2024
DOI: 10.18632/aging.205493 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aging, online erschienen am 31.01.2024. Verfasst von Qiang Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Suining Central Hospital, Suining 629000, Sichuan, P.R. China. Hauptthemen laut MEDLINE: Brain Neoplasms, Glioma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Mitochondrial ribosomal protein S23 (MRPS23), a component of the ribosome small subunit, has been reported to be overexpressed in various cancers and has been predicted to be involved in increased cell proliferation. It has been confirmed that MRPS23 was involved in the regulation of breast cancer and hepatocellular carcinoma cell proliferation. However, little is known about the function of MRPS23 in glioma. In this study, we found that MRPS23 expression was higher in gliomas than in adjacent normal tissues. Higher expression of MRPS23 in gliomas correlated with poorer prognosis, unfavorable histological features, absence of mutations in the isocitrate dehydrogenase gene (IDH), absence of chromosome 1p and 19q deletions, and responses to chemoradiotherapy. Univariate and multivariate Cox analysis demonstrated MRPS23 expression was independently prognostic of overall survival, disease-free survival, and progression-free survival in patients with glioma. KEGG enrichment analysis results indicated that high MRPS23 expression was associated with cell proliferation and immune response-related signaling pathways. We also confirmed that MRPS23 was highly expressed in glioma cells lines, and MRPS23 knockdown significantly reduced cell survival, proliferation, and migration of glioma cells lines. Collectively, these findings offer mechanistic insights into how MRPS23 during glioma progression, and identify MRPS23 as a potential therapeutic target in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Surgery, Suining Central Hospital, Suining 629000, Sichuan, P.R. China.
- Department of Gynaecology, Suining Central Hospital, Suining 629000, Sichuan, P.R. China.
- Department of Oncology, Suining Central Hospital, Suining 629000, Sichuan, P.R. China.
- Department of Pathology, Suining Central Hospital, Suining 629000, Sichuan, P.R. China.
Zitieren
APA
Wang, Q., Chen, G., Liu, L., Peng, X., Yang, X., Yang, L., & Li, C. (2024). MRPS23 is a novel prognostic biomarker and promotes glioma progression. Aging. https://doi.org/10.18632/aging.205493
Vancouver
Wang Q, Chen G, Liu L, Peng X, Yang X, Yang L, et al. MRPS23 is a novel prognostic biomarker and promotes glioma progression. Aging. 2024. doi:10.18632/aging.205493
BibTeX
@article{Wang2024,
author = {Wang, Qiang and Chen, Guiqing and Liu, Liang and Peng, Xiaoying and Yang, Xian and Yang, Ling and Li, Chunhong},
title = {MRPS23 is a novel prognostic biomarker and promotes glioma progression},
journal = {Aging},
year = {2024},
doi = {10.18632/aging.205493}
}
EUVIMED